Nivolumab/pembrolizumabTuberculosis: 2 case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1742卷 / 1期

关键词：

D O I：

10.1007/s40278-019-58634-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：176 / 176

相关论文

共 50 条

[1] PembrolizumabTuberculosis: case report
Reactions Weekly, 2018, 1686 (1) : 289 - 289
[2] Nivolumab/pembrolizumabColitis: 2 case report
Reactions Weekly, 2020, 1808 (1) : 232 - 232
[3] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: 2 case report
Reactions Weekly, 2022, 1909 (1) : 304 - 304
[4] Nivolumab/vemurafenibVitiligo: case report
Reactions Weekly, 2017, 1656 (1) : 365 - 365
[5] Nivolumab/pembrolizumabThyroiditis: case report
Reactions Weekly, 2024, 2039 (1) : 444 - 444
[6] Ipilimumab/nivolumab/nivolumab/prednisoneVarious toxicities: case report
Reactions Weekly, 2023, 1963 (1) : 305 - 305
[7] Nivolumab/pembrolizumabPneumonia: case report
Reactions Weekly, 2021, 1846 (1) : 243 - 243
[8] Nivolumab/prednisoloneHyperthyroidism: case report
Reactions Weekly, 2017, 1666 (1) : 228 - 228
[9] Nivolumab/pembrolizumabHypothyroidism: case report
Reactions Weekly, 2022, 1930 (1) : 448 - 448
[10] Nivolumab/relatlimabCholangitis: case report
Reactions Weekly, 2021, 1847 (1) : 364 - 364

← 1 2 3 4 5 →